Zacks Rating on ABIOMED (ABMD)

ABIOMED (ABMD) : Zacks Investment Research ranks ABIOMED (ABMD) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 7 research analysts is 1.71, which indicates as a Buy.

ABIOMED (ABMD) : The highest short term price target forecast on ABIOMED (ABMD) is $145 and the lowest target price is $101. A total of 5 equity analysts are currently covering the company. The average price of all the analysts is $124.4 with a standard deviation of $18.88.


ABIOMED, Inc. has dropped 1.14% in the last five trading days, however, the shares have posted positive gains of 5.63% in the last 4 weeks. ABIOMED, Inc. is up 21.53% in the last 3-month period. Year-to-Date the stock performance stands at 34.11%. ABIOMED (NASDAQ:ABMD): stock turned positive on Tuesday. Though the stock opened at $121.01, the bulls momentum made the stock top out at $121.48 level for the day. The stock recorded a low of $120.57 and closed the trading day at $121.07, in the green by 0.33%. The total traded volume for the day was 346,735. The stock had closed at $120.67 in the previous days trading.

Abiomed, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Companys products include Impella 2.5, a percutaneous micro heart pump with an integrated motor and sensors; Impella CP, which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD, a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000, a circulatory support system for the temporary support of acute heart failure patients in profound shock, and Symphony, a minimally invasive implantable cardiac assist device.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.